Literature DB >> 2653064

Management of variceal hemorrhage in the potential liver transplant candidate.

R A Crass1, E B Keeffe, C W Pinson.   

Abstract

The increased utilization of liver transplantation raises new issues regarding the management of bleeding esophageal varices in patients who are or may become transplant candidates. Since December 1982, 53 patients were referred from a university hospital to distant liver transplant centers for transplantation. Transplants were performed in 37 patients; at last follow-up, 6 died before transplantation, 7 were awaiting transplantation, and 3 were declined. Of the 53 patients referred for transplantation, 22 (42 percent) had a history of variceal hemorrhage. Sclerotherapy was required in nine patients and portosystemic shunt in four patients. Variceal hemorrhage contributed to the deaths of three of the six patients who died before transplantation could be performed. Endoscopic sclerotherapy has become the mainstay of invasive therapy in most patients with bleeding esophageal varices. If sclerotherapy is unsuccessful in the arrest or control of variceal hemorrhage, the decision must be made whether to proceed with urgent liver transplantation or portosystemic shunt. Factors which influence this choice include the ability to stabilize an acutely bleeding patient, the hepatic reserve and general clinical stature of a patient, and the availability of a liver transplant center.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2653064     DOI: 10.1016/0002-9610(89)90638-7

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

1.  Liver transplantation in patients with previous portasystemic shunt.

Authors:  V Mazzaferro; S Todo; A G Tzakis; A C Stieber; L Makowka; T E Starzl
Journal:  Am J Surg       Date:  1990-07       Impact factor: 2.565

2.  Impact of transjugular intrahepatic portosystemic shunt on orthotopic liver transplantation.

Authors:  F Menegaux; E Baker; E B Keeffe; H Monge; H Egawa; C O Esquivel
Journal:  World J Surg       Date:  1994 Nov-Dec       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.